Bal Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Multiple promoters and promoter-group entities of Bal Pharma Limited have filed annual declarations with BSE and NSE confirming that none of them created any encumbrance (such as pledge, lien, or charge) on their shareholding in the company, either directly or indirectly, during the financial year ended March 31, 2025. The declarations were submitted by individuals including Dilip Surana, Anand Surana, Monica Surana, Archana Surana, Shailesh Siroya, Shrenik D Siroya, Jivi Dheerajmal Siroya, Chandraprakash Dheerajmal Siroya, Anita Siroya, Anita Chandraprakash Siroya, Dilip Surana (HUF), as well as the corporate entity Micro Labs Limited. This is a routine yearly compliance requirement under SEBI's takeover regulations and applies to promoters and persons holding more than a specified threshold. The filings are dated April 1–2, 2025, and were copied to the Chairman of the Audit Committee of Bal Pharma. No encumbrance-related disclosures or changes have been triggered by these declarations.
This is a routine regulatory compliance filing with no direct impact on the stock price. The absence of any new pledges on promoter shares is a mildly reassuring sign, indicating the promoter group is not facing immediate liquidity pressure, but investors should not read it as a major positive trigger.